Zomiradomide - CAS 2655656-99-6

Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-κB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.

IKZF, IRAK, NF-κB, PROTACs, IFNAR

PROTAC, Immunology/Inflammation, NF-κB

2655551

0.9841

C45H48F3N7O6S

871.97

C(N1CC2(C1)CC(CCNC3=C4C(C(=O)N(C4=O)C5C(=O)NC(=O)CC5)=CC=C3)C2)[C@H]6CC[C@@H](CC6)C=7SC=8C(N7)=CC(C(C)(C)O)=C(NC(=O)C=9N=C(C(F)(F)F)C=CC9)C8

-20°C

Ice Packs

Small Compound